Bausch boosted ahead of eye spin-off

Despite various products being marketed for dry eye disease, there is still an unmet need in the disorder. This explains why the late-stage pipeline is relatively crowded, with many different mechanisms being tested.

One of these projects, Bausch Health Companies' NOV03, yesterday succeeded in its first phase 3 trial, Gobi. The project will have to repeat the trick in its second pivotal study, Mojave, but if it does NOV03 could become a key product for the new-look Bausch & Lomb, which is set to spin off from its parent company.